$BETRF

BetterLife Pharma Inc.

BetterLife Pharma is a biopharmaceutical company developing patented pharmaceuticals. Its pipeline includes BETR-001, an oral, non-hallucinogenic 2-bromo-LSD candidate being developed for mental health, headache and other neurological disorders; MM-001, a topical interferon-alpha 2b cream for local intravaginal use to treat cervical intraepithelial neoplasia; and MM-003, an inhaled interferon-alpha 2b formulation being developed for respiratory viral infections. MM-001 and MM-003 are in the pipeline of its subsidiary MedMelior Inc. BetterLife uses contract development and manufacturing organizations on a fee-for-service basis for research, development and production, and plans to rely on contract manufacturers for larger-scale production. It leases its head office in Vancouver, British Columbia, Canada.

No enriched coverage for $BETRF in the last 7 days.

No SEC Form 4 filings for $BETRF in the last 30 days.

See all $BETRF insider activity →
Low

BetterLife Pharma Announces Stock Option Grant

BetterLife Pharma (CSE: BETR) granted 300,000 stock options to a Scientific Advisory Board member, exercisable at C$0.25 per share. The options vest over 24 months and are part of the company's long-term incentive plan. BetterLife is developing BETR-001, a non-hallucinogenic LSD derivative, for chronic cluster headaches and migraines, with an IND application planned for Q1 2027.

BetterLife Pharma (BETR) Reports BETR-001 Preclinical Findings

BetterLife Pharma (BETR) reported preclinical findings for BETR-001, showing gene-expression changes in mice linked to neuroplasticity and stress signaling, similar to LSD effects. The company plans to submit an IND in Q1 2027 and start clinical trials in 2027.

BetterLife Pharma Inc. (BETR) Settles Director's $2M Claim

BetterLife Pharma Inc. settled a $2.0M claim from a director related to a convertible debenture. The director owns about 9.19% of the company's shares. The settlement is final, and shareholder approval of the advance notice policy is pending.

BETRF sentiment & insider activity

Recent BETRF coverage spans financial news, corporate actions and technology.

What's driving BETRF

  • BetterLife Pharma (CSE: BETR) granted 300,000 stock options to a Scientific Advisory Board member, exercisable at C$0.25 per share. The options vest over 24 months and are part of the company's long-term incentive plan. BetterLife is developing BETR-001, a non-hallucinogenic LSD derivative, for chronic cluster headaches and migraines, with an IND application planned for Q1 2027.

    owensoundsuntimes.com · Nov 17, 2026

  • BetterLife Pharma (BETR) reported preclinical findings for BETR-001, showing gene-expression changes in mice linked to neuroplasticity and stress signaling, similar to LSD effects. The company plans to submit an IND in Q1 2027 and start clinical trials in 2027.

    tradingview.com · Nov 17, 2026

  • BetterLife Pharma Inc. settled a $2.0M claim from a director related to a convertible debenture. The director owns about 9.19% of the company's shares. The settlement is final, and shareholder approval of the advance notice policy is pending.

    tradingview.com · Nov 6, 2026

  • BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) announced Tony Pullen's resignation from its board, effective November 4, 2026, and his continued role as an advisor. Henry Chow, CPA, CA, was appointed as a new director. Pullen brought life sciences investment experience, while Chow has extensive public company audit experience. The company is developing BETR-001 for chronic cluster headache and chronic migraine.

    stocktitan.net · Nov 5, 2026

  • BetterLife Pharma (CSE:BETR, OTCQB:BETRF, FSE:NPAU) appointed Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board. Dr. Lipton is a renowned neurology expert and has authored over 1,200 publications. The company granted him options for 500,000 shares. BetterLife is developing BETR-001 for chronic headache and migraine treatment.

    investing.com · Oct 19, 2026

AlphAI scores every news story that mentions BETRF with an AI model for sentiment and relevance, and aggregates insider trades from BetterLife Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BETRF

Score

BetterLife Pharma Announces Stock Option Grant

BetterLife Pharma (CSE: BETR) granted 300,000 stock options to a Scientific Advisory Board member, exercisable at C$0.25 per share. The options vest over 24 months and are part of the company's long-term incentive plan. BetterLife is developing BETR-001, a non-hallucinogenic LSD derivative, for chronic cluster headaches and migraines, with an IND application planned for Q1 2027.

A departing director will stay with BetterLife Pharma as an adviser.

BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) announced Tony Pullen's resignation from its board, effective November 4, 2026, and his continued role as an advisor. Henry Chow, CPA, CA, was appointed as a new director. Pullen brought life sciences investment experience, while Chow has extensive public company audit experience. The company is developing BETR-001 for chronic cluster headache and chronic migraine.

BetterLife Pharma names Richard Lipton as SAB co-chair

BetterLife Pharma (CSE:BETR, OTCQB:BETRF, FSE:NPAU) appointed Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board. Dr. Lipton is a renowned neurology expert and has authored over 1,200 publications. The company granted him options for 500,000 shares. BetterLife is developing BETR-001 for chronic headache and migraine treatment.

The researcher whose work led to migraine medicines used by millions will guide BetterLife’s headache program.

BetterLife Pharma (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has formed a Scientific Advisory Board, appointing Professor Peter Goadsby as Co-Chair to guide the development of BETR-001 for chronic cluster headache and chronic migraine. Goadsby is recognized for his research on CGRP, a key driver of migraine. The company granted him stock options for 500,000 shares. BETR-001 is an investigational product not yet approved by any regulatory authority.

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma (CSE: BETR) closed a US$100M offering, issuing 447M common shares at CDN$0.25 each and 108M pre-funded warrants. Proceeds will fund BETR-001 clinical trials for neurological disorders. Investors include Deep Track Capital and other healthcare-focused funds. The company granted agents a 7% commission and warrants.

BetterLife Pharma Inc.: BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants

BetterLife Pharma Inc. (CSE: BETR) filed a final prospectus for a US$100 million public offering of common shares and pre-funded warrants. The offering, led by Bloom Burton Securities and Haywood Securities, aims to raise up to US$100 million with a minimum of US$80 million. Proceeds will fund clinical trials for neurological disorder treatments and general corporate purposes. The offering is expected to close on or around September 17, 2026, subject to regulatory approvals.

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FSE: NPAU) appointed Charles Duncan, PhD, as Director and Chair of the Audit Committee. Dr. Duncan has 30 years of biotechnology and capital markets experience. The company granted him stock options for 500,000 shares, vesting over 24 months, and 125,000 shares, vesting over 3 months. BetterLife focuses on developing BETR-001 for migraine and headache disorders.

Related tickers